NZ336548A - Stable liquid interferon formulations comprising an amino acid as the stabilising agent - Google Patents

Stable liquid interferon formulations comprising an amino acid as the stabilising agent

Info

Publication number: NZ336548A
Authority: NZ; New Zealand
Prior art keywords: interferon; liquid composition; beta; liquid; vessel
Prior art date: 1996-12-24

Application number

NZ336548A

Other languages

English (en)

Inventor

Mary D Dibiasi

Mark Staples

Wen-Li Chung

Eric Scharin

Original Assignee

Biogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-24

Filing date

1997-12-23

Publication date

2001-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ336548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-12-23 Application filed by Biogen Inc filed Critical Biogen Inc

2001-07-05 Priority to NZ512792A priority Critical patent/NZ512792A/xx

2001-09-28 Publication of NZ336548A publication Critical patent/NZ336548A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 132
102000014150 Interferons Human genes 0.000 title claims abstract description 116
108010050904 Interferons Proteins 0.000 title claims abstract description 116
229940079322 interferon Drugs 0.000 title claims abstract description 99
239000007788 liquid Substances 0.000 title claims abstract description 95
150000001413 amino acids Chemical class 0.000 title claims abstract description 31
239000003381 stabilizer Substances 0.000 title claims abstract description 27
238000009472 formulation Methods 0.000 title claims description 45
102000003996 Interferon-beta Human genes 0.000 claims abstract description 115
108090000467 Interferon-beta Proteins 0.000 claims abstract description 115
229960001388 interferon-beta Drugs 0.000 claims abstract description 112
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 57
239000000872 buffer Substances 0.000 claims abstract description 57
239000004471 Glycine Substances 0.000 claims abstract description 28
239000004475 Arginine Substances 0.000 claims abstract description 20
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 20
239000000463 material Substances 0.000 claims abstract description 19
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 15
UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims abstract description 4
102000008070 Interferon-gamma Human genes 0.000 claims abstract description 4
108010074328 Interferon-gamma Proteins 0.000 claims abstract description 4
229940099563 lactobionic acid Drugs 0.000 claims abstract description 4
229940044627 gamma-interferon Drugs 0.000 claims abstract description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 74
235000018102 proteins Nutrition 0.000 claims description 48
108090000623 proteins and genes Proteins 0.000 claims description 48
102000004169 proteins and genes Human genes 0.000 claims description 48
238000000034 method Methods 0.000 claims description 44
239000012669 liquid formulation Substances 0.000 claims description 41
239000011780 sodium chloride Substances 0.000 claims description 35
238000003860 storage Methods 0.000 claims description 30
229940024606 amino acid Drugs 0.000 claims description 29
235000001014 amino acid Nutrition 0.000 claims description 29
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 26
239000001301 oxygen Substances 0.000 claims description 26
229910052760 oxygen Inorganic materials 0.000 claims description 26
229960003121 arginine Drugs 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 18
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 16
229960003589 arginine hydrochloride Drugs 0.000 claims description 16
230000000694 effects Effects 0.000 claims description 16
230000000840 anti-viral effect Effects 0.000 claims description 14
229920001296 polysiloxane Polymers 0.000 claims description 14
230000008569 process Effects 0.000 claims description 14
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 12
230000002378 acidificating effect Effects 0.000 claims description 11
210000004369 blood Anatomy 0.000 claims description 11
239000008280 blood Substances 0.000 claims description 11
-1 polytetrafluoroethylene Polymers 0.000 claims description 10
108091006905 Human Serum Albumin Proteins 0.000 claims description 9
102000008100 Human Serum Albumin Human genes 0.000 claims description 9
229960002449 glycine Drugs 0.000 claims description 9
239000007853 buffer solution Substances 0.000 claims description 8
229960002989 glutamic acid Drugs 0.000 claims description 8
239000008363 phosphate buffer Substances 0.000 claims description 8
229920001993 poloxamer 188 Polymers 0.000 claims description 8
229920001343 polytetrafluoroethylene Polymers 0.000 claims description 8
239000004810 polytetrafluoroethylene Substances 0.000 claims description 8
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 7
239000004615 ingredient Substances 0.000 claims description 7
239000008351 acetate buffer Substances 0.000 claims description 6
238000007911 parenteral administration Methods 0.000 claims description 6
230000000087 stabilizing effect Effects 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 5
238000004108 freeze drying Methods 0.000 claims description 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
235000013922 glutamic acid Nutrition 0.000 claims description 3
239000004220 glutamic acid Substances 0.000 claims description 3
150000007524 organic acids Chemical group 0.000 claims description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
239000000853 adhesive Substances 0.000 claims description 2
230000001070 adhesive effect Effects 0.000 claims description 2
229940050410 gluconate Drugs 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
238000001179 sorption measurement Methods 0.000 abstract description 6
239000000546 pharmaceutical excipient Substances 0.000 description 34
235000011468 Albizia julibrissin Nutrition 0.000 description 31
241001070944 Mimosa Species 0.000 description 31
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 23
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
239000000243 solution Substances 0.000 description 18
229910019142 PO4 Inorganic materials 0.000 description 17
229940047124 interferons Drugs 0.000 description 17
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 17
239000010452 phosphate Substances 0.000 description 17
238000002360 preparation method Methods 0.000 description 16
210000004027 cell Anatomy 0.000 description 15
241000894007 species Species 0.000 description 15
238000002347 injection Methods 0.000 description 13
239000007924 injection Substances 0.000 description 13
238000001262 western blot Methods 0.000 description 13
229910052786 argon Inorganic materials 0.000 description 12
238000003556 assay Methods 0.000 description 12
230000000120 cytopathologic effect Effects 0.000 description 12
239000011521 glass Substances 0.000 description 12
238000011282 treatment Methods 0.000 description 12
230000006240 deamidation Effects 0.000 description 11
210000002966 serum Anatomy 0.000 description 11
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
229910052757 nitrogen Inorganic materials 0.000 description 10
239000000047 product Substances 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 9
238000002835 absorbance Methods 0.000 description 9
238000010790 dilution Methods 0.000 description 9
239000012895 dilution Substances 0.000 description 9
238000001155 isoelectric focusing Methods 0.000 description 9
BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 9
238000011084 recovery Methods 0.000 description 9
235000017281 sodium acetate Nutrition 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
101001054334 Homo sapiens Interferon beta Proteins 0.000 description 8
229930195725 Mannitol Natural products 0.000 description 8
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
229930006000 Sucrose Natural products 0.000 description 8
241000700605 Viruses Species 0.000 description 8
239000007789 gas Substances 0.000 description 8
239000000594 mannitol Substances 0.000 description 8
235000010355 mannitol Nutrition 0.000 description 8
201000006417 multiple sclerosis Diseases 0.000 description 8
239000005720 sucrose Substances 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
239000002253 acid Substances 0.000 description 7
239000011261 inert gas Substances 0.000 description 7
238000007918 intramuscular administration Methods 0.000 description 7
229960003646 lysine Drugs 0.000 description 7
239000001632 sodium acetate Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
239000004472 Lysine Substances 0.000 description 6
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
229920002684 Sepharose Polymers 0.000 description 6
230000002776 aggregation Effects 0.000 description 6
238000004220 aggregation Methods 0.000 description 6
238000000746 purification Methods 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
238000004007 reversed phase HPLC Methods 0.000 description 6
239000000523 sample Substances 0.000 description 6
239000001488 sodium phosphate Substances 0.000 description 6
229910000162 sodium phosphate Inorganic materials 0.000 description 6
235000011008 sodium phosphates Nutrition 0.000 description 6
238000012360 testing method Methods 0.000 description 6
238000002834 transmittance Methods 0.000 description 6
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
239000008215 water for injection Substances 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000007423 decrease Effects 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
239000012467 final product Substances 0.000 description 5
238000012510 peptide mapping method Methods 0.000 description 5
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
208000032843 Hemorrhage Diseases 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
230000008033 biological extinction Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
229910002092 carbon dioxide Inorganic materials 0.000 description 4
230000008859 change Effects 0.000 description 4
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
230000002500 effect on skin Effects 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
230000007794 irritation Effects 0.000 description 4
238000002093 isoelectric focusing polyacrylamide gel electrophoresis Methods 0.000 description 4
239000000178 monomer Substances 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
230000003285 pharmacodynamic effect Effects 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
239000002994 raw material Substances 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
125000003396 thiol group Chemical group [H]S* 0.000 description 4
241000282412 Homo Species 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
206010022095 Injection Site reaction Diseases 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000001502 gel electrophoresis Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
239000012931 lyophilized formulation Substances 0.000 description 3
229960001855 mannitol Drugs 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
238000012216 screening Methods 0.000 description 3
238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 3
238000001542 size-exclusion chromatography Methods 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
229960004793 sucrose Drugs 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
239000011701 zinc Substances 0.000 description 3
BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
238000013459 approach Methods 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
239000007844 bleaching agent Substances 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
229960004926 chlorobutanol Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000009295 crossflow filtration Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000010432 diamond Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
235000019800 disodium phosphate Nutrition 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000036541 health Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
230000003902 lesion Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000002609 medium Substances 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
150000002482 oligosaccharides Chemical class 0.000 description 2
230000008520 organization Effects 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000012545 processing Methods 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000004044 response Effects 0.000 description 2
239000012898 sample dilution Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
229940087562 sodium acetate trihydrate Drugs 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
UPMFZISCCZSDND-JJKGCWMISA-M sodium gluconate Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UPMFZISCCZSDND-JJKGCWMISA-M 0.000 description 2
229940074404 sodium succinate Drugs 0.000 description 2
ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
231100000041 toxicology testing Toxicity 0.000 description 2
238000012546 transfer Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
102000036509 GTP Cyclohydrolase Human genes 0.000 description 1
108010023555 GTP Cyclohydrolase Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
208000012266 Needlestick injury Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
GZLGNNHEHXBCBI-UHFFFAOYSA-L [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O Chemical compound [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O GZLGNNHEHXBCBI-UHFFFAOYSA-L 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000001064 anti-interferon Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
238000011190 asparagine deamidation Methods 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013522 chelant Substances 0.000 description 1
230000009920 chelation Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
KNKDZWFHOIKECV-UHFFFAOYSA-L dipotassium 2,3,4-trihydroxy-4-oxobutanoate Chemical compound [K+].[K+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O KNKDZWFHOIKECV-UHFFFAOYSA-L 0.000 description 1
OQOQSRMIBLJVHE-UHFFFAOYSA-L dipotassium 2-hydroxy-2-oxoacetate Chemical compound [K+].[K+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O OQOQSRMIBLJVHE-UHFFFAOYSA-L 0.000 description 1
WGFMTHGYKYEDHF-UHFFFAOYSA-L disodium 2-hydroxy-2-oxoacetate Chemical compound [Na+].[Na+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O WGFMTHGYKYEDHF-UHFFFAOYSA-L 0.000 description 1
SILCDLWESNHZKB-UHFFFAOYSA-L disodium 4-hydroxy-4-oxobutanoate Chemical compound [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000005684 electric field Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012537 formulation buffer Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000003055 full factorial design Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000013101 initial test Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
238000012933 kinetic analysis Methods 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
238000002356 laser light scattering Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229940039748 oxalate Drugs 0.000 description 1
QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
238000005192 partition Methods 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000004224 potassium gluconate Substances 0.000 description 1
229960003189 potassium gluconate Drugs 0.000 description 1
LCPMNMXCIHBTEX-UHFFFAOYSA-M potassium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [K+].CC(O)C(O)=O.CC(O)C([O-])=O LCPMNMXCIHBTEX-UHFFFAOYSA-M 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000004845 protein aggregation Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
230000036573 scar formation Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
KYOYLUVYCHVYGC-BUOKYLHBSA-M sodium (E)-but-2-enedioic acid (E)-4-hydroxy-4-oxobut-2-enoate Chemical compound [Na+].OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C([O-])=O KYOYLUVYCHVYGC-BUOKYLHBSA-M 0.000 description 1
BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
FKUGSGSUEMPKIL-UHFFFAOYSA-M sodium butanedioic acid dihydrogen phosphate Chemical compound P(=O)([O-])(O)O.C(CCC(=O)O)(=O)O.[Na+] FKUGSGSUEMPKIL-UHFFFAOYSA-M 0.000 description 1
239000000176 sodium gluconate Substances 0.000 description 1
229940005574 sodium gluconate Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
LLVQEXSQFBTIRD-UHFFFAOYSA-M sodium;2,3,4-trihydroxy-4-oxobutanoate;hydrate Chemical compound O.[Na+].OC(=O)C(O)C(O)C([O-])=O LLVQEXSQFBTIRD-UHFFFAOYSA-M 0.000 description 1
KMPHTYSTEHXSTL-UHFFFAOYSA-M sodium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O.CC(O)C([O-])=O KMPHTYSTEHXSTL-UHFFFAOYSA-M 0.000 description 1
VDZDAHYKYRVHJR-UHFFFAOYSA-M sodium;2-hydroxypropanoate;hydrate Chemical compound [OH-].[Na+].CC(O)C(O)=O VDZDAHYKYRVHJR-UHFFFAOYSA-M 0.000 description 1
OESFSXYRSCBAQJ-UHFFFAOYSA-M sodium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC([O-])=O OESFSXYRSCBAQJ-UHFFFAOYSA-M 0.000 description 1
DGPIGKCOQYBCJH-UHFFFAOYSA-M sodium;acetic acid;hydroxide Chemical compound O.[Na+].CC([O-])=O DGPIGKCOQYBCJH-UHFFFAOYSA-M 0.000 description 1
VBGUQBPWJMPQBI-UHFFFAOYSA-M sodium;butanedioic acid;4-hydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)CCC(O)=O.OC(=O)CCC([O-])=O VBGUQBPWJMPQBI-UHFFFAOYSA-M 0.000 description 1
JISIBLCXFLGVJX-UHFFFAOYSA-M sodium;butanedioic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)CCC(O)=O JISIBLCXFLGVJX-UHFFFAOYSA-M 0.000 description 1
KIJIBEBWNNLSKE-UHFFFAOYSA-M sodium;oxalic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)C(O)=O KIJIBEBWNNLSKE-UHFFFAOYSA-M 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000008362 succinate buffer Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
JYXKLAOSCQDVIX-NFMYELBMSA-K trisodium (E)-but-2-enedioate (E)-4-hydroxy-4-oxobut-2-enoate Chemical compound [Na+].[Na+].[Na+].OC(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O JYXKLAOSCQDVIX-NFMYELBMSA-K 0.000 description 1
XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Immunology (AREA)
Virology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Zoology (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
AIDS & HIV (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NZ336548A 1996-12-24 1997-12-23 Stable liquid interferon formulations comprising an amino acid as the stabilising agent NZ336548A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
NZ512792A NZ512792A (en)	1996-12-24	2001-07-05	Stable liquid interferon beta formulations

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3435396P	1996-12-24	1996-12-24
PCT/US1997/023817 WO1998028007A1 (en)	1996-12-24	1997-12-23	Stable liquid interferon formulations

Publications (1)

Publication Number	Publication Date
NZ336548A true NZ336548A (en)	2001-09-28

Family

ID=21875893

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NZ336548A NZ336548A (en)	1996-12-24	1997-12-23	Stable liquid interferon formulations comprising an amino acid as the stabilising agent
NZ512792A NZ512792A (en)	1996-12-24	2001-07-05	Stable liquid interferon beta formulations

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NZ512792A NZ512792A (en)	1996-12-24	2001-07-05	Stable liquid interferon beta formulations

Country Status (27)

Country	Link
EP (1)	EP0948358B2 (is)
JP (5)	JP4878664B2 (is)
KR (2)	KR101042660B1 (is)
CN (2)	CN1222315C (is)
AT (1)	ATE270899T1 (is)
AU (1)	AU738362B2 (is)
BG (2)	BG65418B1 (is)
BR (1)	BR9714434A (is)
CA (1)	CA2275890C (is)
CZ (1)	CZ300636B6 (is)
DE (1)	DE69729880T3 (is)
DK (1)	DK0948358T4 (is)
EA (1)	EA002754B1 (is)
EE (2)	EE04266B1 (is)
ES (1)	ES2224290T5 (is)
HU (1)	HU224222B1 (is)
IL (1)	IL130524A (is)
IS (1)	IS2070B (is)
MX (1)	MX337876B (is)
NO (1)	NO327844B1 (is)
NZ (2)	NZ336548A (is)
PL (1)	PL193447B1 (is)
PT (1)	PT948358E (is)
SI (1)	SI0948358T2 (is)
SK (1)	SK284989B6 (is)
TR (1)	TR199901968T2 (is)
WO (1)	WO1998028007A1 (is)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7732405B2 (en)	2003-08-14	2010-06-08	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en)	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
US8299029B2 (en)	2002-06-21	2012-10-30	Novo Nordisk Health Care Ag	Stabilised solid compositions of factor VII polypeptides
US8461116B2 (en)	2001-12-21	2013-06-11	Novo Nordisk Healthcare Ag	Liquid composition of factor VII polypeptides
US8536127B2 (en)	2003-05-23	2013-09-17	Novo Nordisk Healthcare Ag	Protein stabilization in solution
US8658597B2 (en)	2003-12-19	2014-02-25	Novo Nordisk Healthcare Ag	Stabilised compositions of factor VII polypeptides

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030190307A1 (en)	1996-12-24	2003-10-09	Biogen, Inc.	Stable liquid interferon formulations
SI0948358T2 (sl) *	1996-12-24	2012-03-30	Biogen Idec Inc	Stabilne tekoče formulacije interferona
DK1017413T4 (da) *	1997-09-23	2008-03-25	Rentschler Biotech Gmbh	Flydende formulering af interferon-beta
ATE359809T1 (de) *	1999-05-31	2007-05-15	Mitsubishi Chem Corp	Gefriergetrocknete hgf-präparationen
US6887462B2 (en)	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
UY27373A1 (es) *	2001-07-09	2003-02-28	Schering Ag	Formulaciones de interferón beta-humano
WO2003061687A1 (fr) *	2002-01-18	2003-07-31	Asahi Kasei Pharma Corporation	Preparation a concentration elevee de thrombomoduline soluble
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
TWI272948B (en)	2003-05-01	2007-02-11	Ares Trading Sa	HSA-free stabilized interferon liquid formulations
AR044302A1 (es) *	2003-05-13	2005-09-07	Ares Trading Sa	Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
CN1318087C (zh) *	2003-06-06	2007-05-30	北京三诺佳邑生物技术有限责任公司	去白蛋白神经生长因子制剂
BRPI0416042A (pt) *	2003-11-13	2007-01-02	Alza Corp	composição e aparelho para suprimento transdérmico
EP1532983A1 (en) *	2003-11-18	2005-05-25	ZLB Bioplasma AG	Immunoglobulin preparations having increased stability
MXPA06014079A (es) *	2004-06-01	2007-02-15	Ares Trading Sa	Metodo para estabilizar proteinas.
KR101149454B1 (ko) *	2004-08-24	2012-05-25	간가와 겐지	생리활성 펩티드의 액상 제제
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
ES2318575T3 (es) *	2004-11-10	2009-05-01	Novartis Vaccines And Diagnostics, Inc.	Interferon beta desamidado.
CN107028760B (zh) *	2005-01-12	2019-11-01	比奥根Ma公司	运输干扰素-β的方法
US20060188555A1 (en) *	2005-01-21	2006-08-24	Micheal Cormier	Therapeutic peptide formulations with improved stability
ATE501248T1 (de)	2005-07-02	2011-03-15	Arecor Ltd	Stabile wässrige systeme mit proteinen
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
CN102838599A (zh)	2006-05-04	2012-12-26	贝林格尔.英格海姆国际有限公司	多晶型
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
JP5812318B2 (ja) *	2007-12-04	2015-11-11	レメディーファーマシューティカルズ，インコーポレイテッド	凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物
BRPI0821029A2 (pt)	2007-12-20	2015-06-16	Merck Serono Sa	Fomulações de peg-interferon-beta
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
WO2009133408A2 (en)	2008-05-01	2009-11-05	Arecor Limited	Protein formulation
EP2328607A1 (en)	2008-07-16	2011-06-08	Arecor Limited	Stable formulation of a therapeutic protein
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt)	2008-09-10	2015-12-15	Boehring Ingelheim Internat Gmbh	teriapia de combinação para tratamento de diabetes e condições relacionadas.
DE102008051574A1 (de)	2008-10-14	2010-04-15	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru)	2008-12-23	2015-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Солевые формы органического соединения
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009032179A1 (de)	2009-07-07	2011-01-13	Biogenerix Ag	Verfahren zur Reinigung von Interferon beta
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP6078344B2 (ja)	2010-02-04	2017-02-08	ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト	免疫グロブリン製剤
EP2361636A1 (en)	2010-02-26	2011-08-31	CSL Behring AG	Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) *	2010-03-15	2011-09-15	Kurt Koch	Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
WO2011138421A1 (en)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combination therapy
NZ603319A (en)	2010-06-24	2015-04-24	Boehringer Ingelheim Int	Diabetes therapy
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN103260616B (zh) *	2010-12-09	2015-09-09	丸石制药株式会社	对乙酰氨基酚的稳定化剂
WO2012125809A1 (en)	2011-03-15	2012-09-20	Biogen Idec Inc.	Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
CA2841552C (en)	2011-07-15	2020-06-23	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP2838571A4 (en) *	2012-04-19	2016-02-10	Bard Inc C R	INFUSATE WITH INCREASED PH STABILITY IN ETHYLENE OXIDE STERILIZATION
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it)	2012-05-28	2013-11-29	Nicoletta Maxia	Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) *	2013-03-07	2014-11-05	安徽安科生物工程（集团）股份有限公司	一种重组人干扰素α2b制剂
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
JP2014208669A (ja) *	2014-06-17	2014-11-06	株式会社スリー・ディー・マトリックス	タンパク質の凝集抑制剤
HUE052280T2 (hu)	2014-12-03	2021-04-28	Csl Behring Ag	Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
KR101943160B1 (ko) *	2016-10-06	2019-01-30	에이비온 주식회사	인터페론 베타 변이체의 안정화 제제
AU2018321335B2 (en)	2017-08-22	2025-08-14	Biogen Ma Inc.	Pharmaceutical compositions containing anti-beta amyloid antibodies
KR102731889B1 (ko) *	2019-07-18	2024-11-19	에이비온 주식회사	2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) *	2019-11-20	2023-04-07	迈克生物股份有限公司	蛋白c活性测定试剂盒
CA3177028A1 (en) *	2020-04-29	2021-11-04	Jun Young Choi	Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
WO2022207655A1 (en) *	2021-03-30	2022-10-06	Schott Schweiz Ag	System for low-temperature storage of a pharmaceutical composition, liquid composition, method and uses
CN114177273B (zh) *	2021-11-29	2024-05-28	苏州人本药业有限公司	一种含有神经毒素的液体制剂及其制备方法
JP2025501169A (ja) *	2021-12-27	2025-01-17	エナラーレセラピューティクスインコーポレイテッド	呼吸刺激薬非経口製剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57175125A (en) *	1981-04-20	1982-10-28	Wakunaga Yakuhin Kk	Preparation of beta-interferon
DE3262575D1 (en) *	1981-12-23	1985-04-18	Schering Corp	Stabilised interferon formulations and their preparation
JPS60243028A (ja) *	1984-04-28	1985-12-03	Kyowa Hakko Kogyo Co Ltd	インタ−フエロンの可溶化方法
JPS63196268A (ja) *	1987-02-10	1988-08-15	Kanegafuchi Chem Ind Co Ltd	無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) *	1987-03-13	1988-09-28	Interferon Sciences, Inc.	Lyophilized lymphokine composition
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
US4895716A (en) *	1987-06-09	1990-01-23	Biogen, Inc.	Stabilized formulations of gamma interferons
JPH02124832A (ja) *	1988-07-08	1990-05-14	Toray Ind Inc	インターヘェロンβ組成物
DE3939346A1 (de) *	1989-11-29	1991-06-06	Behringwerke Ag	Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) *	1993-05-12	2001-01-28	Genentech Inc	Stable liquid compositions of gamma interferon
TW249202B (is) *	1993-08-13	1995-06-11	Ciba Gerigy Corp
US5545723A (en) *	1994-03-15	1996-08-13	Biogen Inc.	Muteins of IFN-β
JPH09511745A (ja) *	1994-04-08	1997-11-25	ブリガムアンドウィミンズホスピタル	経口寛容および／またはタイプｉインターフェロンを用いた自己免疫疾患の治療
IT1272252B (it) *	1994-05-16	1997-06-16	Applied Research Systems	Formulazioni liquide di interferone beta
TW426523B (en) *	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
SI0948358T2 (sl) *	1996-12-24	2012-03-30	Biogen Idec Inc	Stabilne tekoče formulacije interferona

1997
- 1997-12-23 SI SI9730670T patent/SI0948358T2/sl unknown
- 1997-12-23 ES ES97952621T patent/ES2224290T5/es not_active Expired - Lifetime
- 1997-12-23 CN CNB971814996A patent/CN1222315C/zh not_active Expired - Lifetime
- 1997-12-23 DE DE69729880T patent/DE69729880T3/de not_active Expired - Lifetime
- 1997-12-23 WO PCT/US1997/023817 patent/WO1998028007A1/en not_active Ceased
- 1997-12-23 CN CN2005100915177A patent/CN1733296B/zh not_active Expired - Lifetime
- 1997-12-23 AT AT97952621T patent/ATE270899T1/de active
- 1997-12-23 SK SK858-99A patent/SK284989B6/sk not_active IP Right Cessation
- 1997-12-23 EE EEP200300127A patent/EE04266B1/xx unknown
- 1997-12-23 NZ NZ336548A patent/NZ336548A/en not_active IP Right Cessation
- 1997-12-23 JP JP52905698A patent/JP4878664B2/ja not_active Expired - Fee Related
- 1997-12-23 EA EA199900597A patent/EA002754B1/ru not_active IP Right Cessation
- 1997-12-23 TR TR1999/01968T patent/TR199901968T2/xx unknown
- 1997-12-23 CA CA2275890A patent/CA2275890C/en not_active Expired - Lifetime
- 1997-12-23 EP EP97952621A patent/EP0948358B2/en not_active Expired - Lifetime
- 1997-12-23 DK DK97952621.7T patent/DK0948358T4/da active
- 1997-12-23 EE EEP199900313A patent/EE04223B1/xx unknown
- 1997-12-23 AU AU56191/98A patent/AU738362B2/en not_active Expired
- 1997-12-23 KR KR1020077010020A patent/KR101042660B1/ko not_active Expired - Lifetime
- 1997-12-23 BR BR9714434-7A patent/BR9714434A/pt active Search and Examination
- 1997-12-23 HU HU0000829A patent/HU224222B1/hu active IP Right Grant
- 1997-12-23 PL PL97334365A patent/PL193447B1/pl unknown
- 1997-12-23 PT PT97952621T patent/PT948358E/pt unknown
- 1997-12-23 CZ CZ0228299A patent/CZ300636B6/cs not_active IP Right Cessation
- 1997-12-23 IL IL13052497A patent/IL130524A/xx not_active IP Right Cessation
- 1997-12-23 KR KR1019997005701A patent/KR20000069664A/ko not_active Ceased
1999
- 1999-06-21 IS IS5087A patent/IS2070B/is unknown
- 1999-06-23 MX MX2012000515A patent/MX337876B/es unknown
- 1999-06-23 NO NO993121A patent/NO327844B1/no not_active IP Right Cessation
- 1999-07-19 BG BG109523A patent/BG65418B1/bg unknown
- 1999-07-19 BG BG103594A patent/BG65171B1/bg unknown
2001
- 2001-07-05 NZ NZ512792A patent/NZ512792A/xx not_active IP Right Cessation
2007
- 2007-05-18 JP JP2007133540A patent/JP2007204501A/ja not_active Withdrawn
2011
- 2011-01-07 JP JP2011002557A patent/JP5851695B2/ja not_active Expired - Lifetime
- 2011-10-04 JP JP2011220534A patent/JP2012006979A/ja not_active Withdrawn
2014
- 2014-02-25 JP JP2014033581A patent/JP2014098029A/ja not_active Withdrawn

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8461116B2 (en)	2001-12-21	2013-06-11	Novo Nordisk Healthcare Ag	Liquid composition of factor VII polypeptides
US8299029B2 (en)	2002-06-21	2012-10-30	Novo Nordisk Health Care Ag	Stabilised solid compositions of factor VII polypeptides
US8729022B2 (en)	2002-06-21	2014-05-20	Novo Nordisk Healthcare Ag	Stabilised solid compositions of factor VII polypeptides
US7897734B2 (en)	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
US8084587B2 (en)	2003-03-26	2011-12-27	Novo Nordisk Health Care Ag	Method for the production of proteins
US8536127B2 (en)	2003-05-23	2013-09-17	Novo Nordisk Healthcare Ag	Protein stabilization in solution
US7732405B2 (en)	2003-08-14	2010-06-08	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
US8026214B2 (en)	2003-08-14	2011-09-27	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
US8318904B2 (en)	2003-08-14	2012-11-27	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
US8658597B2 (en)	2003-12-19	2014-02-25	Novo Nordisk Healthcare Ag	Stabilised compositions of factor VII polypeptides

Also Published As

Publication number	Publication date
DK0948358T4 (da)	2012-03-19
JP2007204501A (ja)	2007-08-16
AU738362B2 (en)	2001-09-13
BG65418B1 (bg)	2008-07-31
CN1245434A (zh)	2000-02-23
MX337876B (es)	2016-03-22
HUP0000829A2 (en)	2000-07-28
BG109523A (en)	2007-05-31
KR20070052363A (ko)	2007-05-21
EP0948358B1 (en)	2004-07-14
BR9714434A (pt)	2000-05-02
EA199900597A1 (ru)	2000-02-28
HK1092048A1 (zh)	2007-02-02
CA2275890C (en)	2011-11-01
ES2224290T5 (es)	2012-03-12
DE69729880T3 (de)	2012-05-10
NO327844B1 (no)	2009-10-05
CN1222315C (zh)	2005-10-12
IS2070B (is)	2005-12-15
PL193447B1 (pl)	2007-02-28
EE04223B1 (et)	2004-02-16
HUP0000829A3 (en)	2002-01-28
ES2224290T3 (es)	2005-03-01
TR199901968T2 (xx)	1999-12-21
JP5851695B2 (ja)	2016-02-03
DE69729880D1 (de)	2004-08-19
EE04266B1 (et)	2004-04-15
CA2275890A1 (en)	1998-07-02
ATE270899T1 (de)	2004-07-15
NO993121D0 (no)	1999-06-23
SI0948358T2 (sl)	2012-03-30
BG65171B1 (bg)	2007-05-31
PL334365A1 (en)	2000-02-28
JP2011068694A (ja)	2011-04-07
NO993121L (no)	1999-08-24
PT948358E (pt)	2004-10-29
HU224222B1 (hu)	2005-06-28
AU5619198A (en)	1998-07-17
KR101042660B1 (ko)	2011-06-20
SI0948358T1 (en)	2005-04-30
NZ512792A (en)	2002-11-26
DK0948358T3 (da)	2004-11-08
IL130524A (en)	2005-08-31
HK1025040A1 (en)	2000-11-03
EA002754B1 (ru)	2002-08-29
JP2012006979A (ja)	2012-01-12
JP4878664B2 (ja)	2012-02-15
CZ300636B6 (cs)	2009-07-08
BG103594A (en)	2000-04-28
IS5087A (is)	1999-06-21
JP2001519770A (ja)	2001-10-23
CN1733296A (zh)	2006-02-15
EE9900313A (et)	2000-04-17
SK85899A3 (en)	2000-01-18
WO1998028007A1 (en)	1998-07-02
IL130524A0 (en)	2000-06-01
EE200300127A (et)	2003-06-16
EP0948358A1 (en)	1999-10-13
DE69729880T2 (de)	2005-07-07
SK284989B6 (sk)	2006-04-06
CN1733296B (zh)	2010-05-26
EP0948358B2 (en)	2011-11-23
CZ228299A3 (cs)	1999-12-15
JP2014098029A (ja)	2014-05-29
KR20000069664A (ko)	2000-11-25

Legal Events

Date	Code	Title
2002-02-01	PSEA	Patent sealed
2002-02-01	RENW	Renewal (renewal fees accepted)
2004-12-24	RENW	Renewal (renewal fees accepted)
2007-12-21	RENW	Renewal (renewal fees accepted)
2011-01-28	RENW	Renewal (renewal fees accepted)
2018-01-26	EXPY	Patent expired